$52.00
All products are provided either as a liquid solution in a 30mL vial or as raw powder packaged in an individual bag.
0.5mg/mL solution (15mg/30mL)
SLU-PP-332 as a pan-ERR agonist and exercise-mimetic probe: enzyme rationale, preclinical pharmacology, systems endpoints, and research-use sourcing from 4-Amino-Labs
Abstract
Estrogen-related receptors (ERRα/β/γ) are ligand-responsive nuclear receptors that coordinate oxidative metabolism, mitochondrial biogenesis, and substrate selection in energetically active tissues. SLU-PP-332 is a small-molecule pan-ERR agonist that activates an ERR-dependent “acute aerobic exercise” transcriptional program, increasing energy expenditure and fatty-acid oxidation in vivo without reducing food intake. In murine models of metabolic syndrome and diet-induced obesity, SLU-PP-332 reduces fat mass, improves lipid parameters, and remodels liver steatosis signatures while shifting respiratory exchange ratio toward greater lipid use; in skeletal muscle, it increases oxidative fiber markers, mitochondrial content, and endurance performance. Here we review receptor biology and coactivator coupling, the pharmacology of SLU-PP-332 in cells and animals, dosing paradigms and route considerations used in published studies, translational biomarkers and experimental endpoints, context-dependent risks and unknowns, and practical guidance for nonclinical study design. We also provide research-use sourcing information from 4-Amino-Labs, which supplies SLU-PP-332 strictly for laboratory research with RUO documentation.
Introduction
ERRα (ESRRA), ERRβ (ESRRB), and ERRγ (ESRRG) are orphan nuclear receptors closely related to classical estrogen receptors but with distinct transcriptional networks. Through interactions with PGC-1 coactivators and chromatin regulators, ERRs govern programs for mitochondrial biogenesis, oxidative phosphorylation (OXPHOS), lipid catabolism, and angiogenesis. Genetic and transcriptomic studies place ERRs at the center of muscular and hepatic fuel handling, thermogenesis, and exercise adaptation. Pharmacologically, activating ERRs is hypothesized to reproduce elements of endurance training by acutely raising oxidative capacity and fat utilization while remodeling metabolic gene expression across muscle, adipose, and liver.
SLU-PP-332 is a chemically tractable agonist developed to engage ERRα/β/γ, with highest potency at ERRα and measurable activity on ERRβ and ERRγ. In cells, it increases expression of canonical ERR target genes and enhances mitochondrial respiration; in vivo, it recapitulates core features of exercise mimetics, including increased energy expenditure at thermoneutrality, a lower respiratory exchange ratio (RER) consistent with enhanced lipid oxidation, and improvements in fat mass and hepatic lipid content in obese mice. Unlike appetite suppressants, SLU-PP-332’s metabolic effects are observed without reductions in food intake and without increased spontaneous activity, indicating a primary action on metabolic programing rather than behavior.
ERR biology, coactivation, and the exercise-mimetic concept
ERRs operate as transcription factors that bind response elements in promoters and enhancers of metabolic genes, recruiting coactivators such as PGC-1α/β and chromatin-remodeling complexes. Exercise and cold exposure induce PGC-1 coactivators, amplifying ERR-dependent gene sets involved in fatty-acid uptake and β-oxidation (for example, CPT1, MCAD), OXPHOS subunits, TCA cycle enzymes, and mitochondrial transcription factors (for example, TFAM). Activation of ERRs can shift myofiber phenotype toward oxidative, increase capillary density and mitochondrial content, and favor lipid use over carbohydrate under resting and submaximal workloads. Small-molecule pan-ERR agonists extend this paradigm by directly potentiating receptor activity, enabling controlled experimental induction of the exercise program in sedentary animals.
Chemistry and receptor pharmacology of SLU-PP-332
SLU-PP-332 is a drug-like small molecule that shows submicromolar to low-nanomolar activation potency for ERRs in reporter assays, with the strongest activity at ERRα and meaningful activation of ERRβ/γ. In C2C12 myoblasts, SLU-PP-332 increases mitochondrial respiration and induces ERR target genes, including markers of lipid oxidation and mitochondrial biogenesis. Selectivity profiling indicates activity on ERRs with minimal cross-activation of classical ERα/ERβ or unrelated nuclear receptors at concentrations relevant to the ERR program. These features make SLU-PP-332 a valuable chemical probe for dissecting ERR-dependent physiology in cells and intact animals.
Preclinical in vivo evidence: energy expenditure, substrate selection, and adiposity
In chow-fed mice kept at thermoneutrality, repeated SLU-PP-332 administration increases energy expenditure, lowers RER (favoring fat over carbohydrate oxidation), and reduces adipocyte size, without changing food intake or spontaneous locomotor activity. In diet-induced obese (DIO) mice, SLU-PP-332 decreases body-weight gain, reduces fat mass, improves plasma lipid profiles, and attenuates liver triglyceride accumulation and neutral-lipid staining. Indirect calorimetry demonstrates higher fatty-acid oxidation and resting energy expenditure after dosing, consistent with an ERR-driven shift toward oxidative metabolism. In leptin-deficient ob/ob mice, SLU-PP-332 similarly increases energy expenditure and reduces adiposity without affecting caloric intake. These outcomes support the concept that pharmacological ERR activation can reorient whole-body fuel use and adipose biology in the absence of behavioral changes.
Skeletal muscle endpoints and functional capacity
Muscle is a primary target of ERR signaling. In vivo, SLU-PP-332 increases oxidative fiber markers (for example, type IIa), cytochrome-c content, mitochondrial DNA abundance, and expression of OXPHOS genes. Functionally, treated mice display enhanced treadmill endurance and a physiological profile resembling trained animals. In cellular models, SLU-PP-332 augments oxygen consumption rate and induces Ddit4 and other metabolic stress-response genes consistent with increased mitochondrial flux. These data anchor the “exercise-mimetic” label in mechanistic and phenotypic readouts encompassing gene expression, mitochondrial content, fiber identity, and performance.
Liver and MASLD-relevant phenotypes
ERR activity influences hepatic lipid handling, including β-oxidation, VLDL assembly, and mitochondrial function. In DIO mice, SLU-PP-332 lowers hepatic neutral-lipid staining and triglyceride content and improves plasma lipid parameters. Gene expression analyses indicate upregulation of fatty-acid catabolic pathways and OXPHOS components, with partial normalization of HFD-induced dysregulation. These findings align with a model in which ERR activation restores mitochondrial oxidative capacity and lipid flux in hepatocytes, contributing to reversal of steatotic features.
Adipose tissue remodeling
ERR-dependent programs in adipose tissue intersect with thermogenesis, lipolysis, and adipocyte mitochondrial function. Histology from treated animals shows smaller adipocytes and reduced fat-pad mass. While ERRs are not the canonical thermogenic receptors like PPARs or β-adrenergic receptors, their downstream gene networks overlap with brown/brite adipocyte mitochondrial machinery, offering one route for increased energy dissipation under SLU-PP-332 exposure.
Food intake, activity, and energy balance
A critical observation in the rodent literature is that SLU-PP-332’s metabolic benefits occur without reductions in food intake and without increases in locomotor activity under thermoneutral conditions. This distinguishes pan-ERR activation from anorexigenic or stimulant mechanisms and emphasizes direct metabolic reprograming. Indirect calorimetry confirms that increased energy expenditure accounts for changes in energy balance during treatment.
Dosing paradigms, route of administration, and exposure considerations
Published in vivo experiments commonly use intraperitoneal (i.p.) administration at 50 mg/kg twice daily for 12–28 days in adult male C57BL/6J or ob/ob mice, with cohorts kept at thermoneutrality and studied by indirect calorimetry (CLAMS) and body-composition analyses. Additional studies have explored once-daily i.p. regimens around 25 mg/kg in chronic disease models. In reporter and cell assays, SLU-PP-332 is active at sub- to low-micromolar concentrations. Detailed plasma pharmacokinetics and absolute oral bioavailability in rodents are still being characterized in the open literature; as a result, most controlled efficacy studies referenced to date use parenteral dosing with defined schedules to sustain ERR activation. For nonclinical design, dose-range finding, route feasibility (i.p., s.c., osmotic minipumps), and exposure–response mapping in the selected strain/sex/age are recommended before hypothesis testing.
Assays, biomarkers, and phenotypic endpoints
Biochemical and transcriptional readouts
ERR target-gene panels spanning fatty-acid uptake/β-oxidation (Cpt1b, Acadl/Acadm), OXPHOS (Ndufs, Uqcrc, Cox), TCA (Cs, Idh), and mitochondrial biogenesis (Ppargc1a, Tfam) provide proximal pharmacodynamic evidence of receptor engagement. In muscle, Ddit4 induction and increases in mitochondrial DNA and cytochrome-c complement expression data. In liver and adipose, gene signatures reflecting enhanced oxidative metabolism and reduced lipogenesis/lipid storage add mechanistic depth.
Energetics and substrate use
Indirect calorimetry at thermoneutrality quantifies energy expenditure, RER, fatty-acid and carbohydrate oxidation rates, and activity. Time-locked dosing and longitudinal monitoring enable assessment of acute versus sustained effects and separation of metabolic from behavioral drivers.
Body composition and histology
DXA or EchoMRI for lean/fat mass, adipocyte morphometrics, and liver Oil Red O or lipidomics form a phenotypic core. Plasma lipids (triglycerides, cholesterol, HDL/LDL), liver enzymes, and glucose/insulin tolerance tests extend systemic profiling.
Safety pharmacology and tolerability in animals
Across short courses, studies report no overt toxicity at efficacious exposures, with normal clinical chemistry and hematology panels under commonly used dosing schedules. Nevertheless, ERRs regulate broad gene networks across heart, brain, kidney, and endocrine tissues; longer studies in disease models (for example, kidney aging) suggest benefits at defined doses, but comprehensive long-term safety pharmacology remains sparse in the public domain. Nonclinical programs should include organ-system panels, cardiovascular telemetry where appropriate, and full pathology review to characterize off-target consequences of chronic ERR activation.
Context dependence, receptor isoforms, and off-target considerations
SLU-PP-332 is a pan-ERR agonist with the strongest potency at ERRα. The relative contribution of ERRβ/γ varies by tissue context, and cross-talk with PPARs, AMPK, and HIF pathways can influence observed phenotypes. While selectivity over classical ERs is reported at relevant concentrations, nuclear-receptor cross-reactivity and downstream network effects remain theoretical risks in longer or higher-exposure studies. These factors motivate transcriptomic and proteomic profiling to detect unanticipated pathway activation, coupled with dose-window optimization to balance metabolic efficacy with system-level perturbations.
Comparators and combinations
Exercise mimetics occupy a diverse space including AMPK activators, PPARδ agonists, and mitochondrial uncouplers. ERR agonism is mechanistically distinct in that it amplifies the transcriptional machinery for oxidative metabolism rather than directly uncoupling mitochondria or stimulating adrenergic pathways. In obese mice, combining ERR activation with dietary control yields additive improvements in fat mass and hepatic features, suggesting compatibility with lifestyle or other pharmacological interventions. Future preclinical work may probe combinations with incretin-based agents or β-oxidation enhancers to define mechanistic complementarity.
Experimental design guidance for investigators
Model selection and housing
Use diet-induced obesity cohorts with pre-randomization by body weight and fat mass, defined sex and age, and thermoneutral housing to decouple thermogenic artifacts. Include leptin-deficient cohorts if mechanistic generalizability is a goal.
Dosing and PK/PD alignment
Select route and schedule that achieve sustained receptor activation within an acceptable tolerability window. Pair dosing with serial pharmacodynamics (ERR target genes, energetics) and, where feasible, exposure measurements (plasma/tissue).
Primary endpoints
Energy expenditure and RER under indirect calorimetry, fat mass and adipocyte size, liver triglyceride content and histology, plasma lipids, and muscle performance form a coherent endpoint suite tied to ERR biology.
Mechanistic modules
Add transcriptomics/epigenomics of muscle and liver, mitochondrial respirometry, and metabolomics for pathway resolution. In adipose, include browning markers and mitochondrial indices to capture tissue-specific remodeling.
Data quality and reporting
Pre-register primary endpoints, report randomization/blinding/power calculations, include sex as a biological variable, and disclose attrition. Provide raw and normalized calorimetry and gene-expression data for reproducibility.
Limitations and open questions
Translational pharmacokinetics and receptor occupancy relationships are early. The durability of metabolic benefits after washout, the consequences of chronic pan-ERR activation in heart and kidney, and the potential for tolerance or compensatory network changes require longer studies. Tissue-targeted delivery or isoform-biased agonists may improve therapeutic index where cardiometabolic benefit is desired with minimal off-target receptor engagement. Finally, while ERR activation reproduces core exercise signatures, exercise itself exerts mechanical, hormonal, neural, and immunologic effects beyond ERR programming; exercise mimetics will not encompass the full scope of training adaptations.
Future directions
First, define exposure–response with quantitative pharmacokinetics and, where possible, receptor-occupancy or target-engagement biomarkers to guide dose selection across tissues. Second, map isoform contributions with tissue-selective readouts and test next-generation ligands for isoform bias. Third, extend models to thermoneutral large-rodent settings with metabolic and cardiovascular telemetry to expand safety margins. Fourth, apply single-cell multi-omics to muscle, liver, and adipose to resolve cell-type-specific responses and intercellular signaling. Finally, evaluate combinations with dietary interventions and orthogonal metabolic agents to delineate additivity versus redundancy within energy-balance networks.
Conclusions
SLU-PP-332 is a robust research probe for inducing an ERR-dependent aerobic-exercise program in vivo, increasing energy expenditure and lipid oxidation and improving adiposity and hepatic lipid metrics in obese mouse models without suppressing food intake. In skeletal muscle, it increases oxidative capacity and endurance, consistent with mitochondrial biogenesis and OXPHOS upregulation. As a pan-ERR agonist with strongest activity at ERRα, it enables mechanistic dissection of receptor-coactivator circuits that couple mitochondrial function to organismal energetics. Translation will hinge on exposure–response mapping, long-term safety pharmacology, and context-aware dosing strategies. For laboratories investigating these questions, RUO-grade SLU-PP-332 is available from 4-Amino-Labs Labs with accompanying documentation to support standardized procurement and study reproducibility.
Research-use notice
All materials and methods discussed are for laboratory research use only. They are not for human consumption or for medical, veterinary, or household use. This article summarizes preclinical literature and does not constitute medical advice or evidence of human safety or efficacy.
SLU-PP-332 is a small-molecule pan-ERR agonist with strongest potency at ERRα that activates an exercise-like metabolic program in skeletal muscle, liver, and adipose tissue. It is used as a chemical probe to study ERR-dependent regulation of oxidative metabolism in cells and animal models.
It binds within the ERR ligand-binding domain and enhances transcriptional activity at ERR response elements, recruiting coactivators such as PGC-1α/β. This upregulates genes involved in fatty-acid uptake/oxidation, OXPHOS, the TCA cycle, and mitochondrial biogenesis, shifting substrate use toward lipids and increasing energy expenditure.
In mice at thermoneutrality, repeated dosing increases energy expenditure, lowers RER, reduces fat mass and adipocyte size, and improves hepatic lipid metrics. Spontaneous activity and food intake typically do not decrease, indicating a primary metabolic mechanism.
Common regimens include 50 mg/kg intraperitoneally twice daily for 12–28 days in C57BL/6J or ob/ob mice, with indirect calorimetry and body-composition endpoints. Some disease-specific studies have used approximately 25 mg/kg per day. Published cell work often uses sub- to low-micromolar concentrations.
Published efficacy studies primarily use parenteral dosing. Definitive oral bioavailability and exposure data remain limited publicly; investigators should perform route-feasibility and exposure studies within their chosen model.
ERR target-gene expression (for example, Ppargc1a, Tfam, OXPHOS subunits), oxygen-consumption rate in cells, and, in vivo, indirect calorimetry parameters (energy expenditure, RER), plus mitochondrial DNA and cytochrome-c content in muscle. In liver, lipidomics and β-oxidation gene panels; in adipose, adipocyte size and mitochondrial markers.
Supplier data sheets report high solubility in DMSO and limited solubility in ethanol, with recommendations for preparing concentrated DMSO stocks and diluting into assay buffers immediately before use. Storage at low temperature is advised; see the supplier’s COA and product page for exact storage guidance and stability.
ERRs regulate broad gene networks; long-term pan-ERR activation could impact heart, kidney, and endocrine pathways. Short-course studies report no overt toxicity at commonly used doses, but programs should include organ-system panels, cardiovascular telemetry where relevant, and pathology review for chronic exposures.
Published data indicate compatibility with dietary interventions, showing additive benefits on adiposity and hepatic features. Rational combinations with orthogonal metabolic agents can be explored, with careful endpoint alignment and safety monitoring.
4-Amino-Labs supplies SLU-PP-332 for laboratory research with COA and RUO terms. Investigators can order at the liquid product page noted above under “Sourcing SLU-PP-332 for research use.”
Typical documentation includes a certificate of analysis and quality disclosures. Researchers remain responsible for institutional approvals (for example, IACUC), hazard assessments, and compliance with applicable regulations.
No. SLU-PP-332 supplied by research vendors is for laboratory research only and is not for human consumption or clinical use. Published studies to date describe cell and animal models.
References
 |
|
| Names | |
|---|---|
| Preferred IUPAC name
4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide
|
|
| Other names
SLU-PP-332
|
|
| Identifiers | |
|
3D model (JSmol)
|
|
| ChemSpider | |
|
PubChem CID
|
|
| Properties | |
| C18H14N2O2 | |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
**The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. Additionally, it is important to note that research chemicals are intended solely for laboratory study by professional researchers and are not intended for human consumption.**
